Posted inBiotechnology
Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through its $3.9 billion…








